Gem investment risk tips
After this stock issue, it is planned to be listed on the gem, which has high investment risk. GEM companies have the characteristics of large investment in innovation, uncertainty about the success of the integration of new and old industries, still in the growth stage, high operation risk, unstable performance and high delisting risk. Investors are facing greater market risk. Investors should fully understand the investment risks of the gem and the risk factors disclosed by the company, and make investment decisions prudently.
Xiamen Weike Jiangnan Mould & Plastic Technology Co.Ltd(000700) Co., Ltd
(on the first floor of No. 1152 and No. 1154 Chunguang Road, Xiamen Torch High tech Zone (Xiang’an) Industrial Zone) IPO and listing on GEM
Sponsor (lead underwriter)
(No. 95, dongchenggenshang street, Qingyang District, Chengdu)
Statement
Any decision or opinion made by the CSRC and the exchange on this issuance does not indicate that they guarantee the authenticity, accuracy and integrity of the registration application documents and the information disclosed, nor do they indicate that they make substantive judgment or guarantee on the profitability, investment value of the issuer or the income of investors. Any statement to the contrary is a false statement.
According to the provisions of the securities law, the issuer shall be responsible for the changes in the operation and income of the issuer after the shares are issued according to law; Investors independently judge the investment value of the issuer, make investment decisions independently, and bear the investment risks caused by changes in the operation and income of the issuer or changes in the stock price after the shares are issued according to law. The issuer and all directors, supervisors and senior managers promise that there are no false records, misleading statements or major omissions in the prospectus and other information disclosure materials, and bear corresponding legal liabilities.
The controlling shareholder and actual controller of the issuer promise that there are no false records, misleading statements or major omissions in this prospectus, and bear corresponding legal liabilities.
The person in charge of the company, the person in charge of accounting and the person in charge of the accounting agency shall ensure that the financial and accounting materials in the prospectus are true and complete.
The issuer and all directors, supervisors, senior managers, controlling shareholders, actual controllers, sponsors and underwriting securities companies promise to compensate investors for losses in securities issuance and trading due to false records, misleading statements or major omissions in the issuer’s prospectus and other information disclosure materials.
The sponsor and the securities service institution promise to compensate the investors for the losses caused to the investors due to the false records, misleading statements or major omissions in the documents prepared and issued for the issuer’s public offering.
Overview of this offering
Type of shares issued: RMB ordinary shares (A shares)
The number of shares issued was 31.2 million, accounting for 25% of the total share capital after issuance. All the shares issued this time are new shares, not involving the public offering of shares by the company’s shareholders.
The par value of each share is RMB 1.00
The issue price per share is 64.08 yuan / share
Issue date: December 30, 2021
Stock exchange and gem of Shenzhen Stock Exchange to be listed
The total share capital after issuance is 124.8 million shares
Sponsor (lead underwriter) Sinolink Securities Co.Ltd(600109)
Signing date of prospectus: January 6, 2022
Tips on major events
This “important event reminder” reminds investors of the company’s risks and other important matters that need special attention. Investors should carefully read the text of the prospectus before making investment decisions. 1、 Special risk tips
Please carefully read the full text of the chapter “risk factors” and pay special attention to the following risks: (I) innovation risk
The downstream market of the company is mainly distributed in industries such as electronics, automobile, household appliances and health appliances. Customers are widely distributed, and the product upgrading is faster and faster, the product structure is more and more complex, and the requirements for precision injection molds, injection molded parts and corresponding suppliers are higher and higher. At the same time, new materials, new processes and information technology applications not only bring opportunities to industry applications, but also bring challenges, promoting the company’s continuous innovation. However, if the company’s innovation ability in technology and product R & D is insufficient and its market competitiveness decreases in the future, it may not be able to meet the product needs of customers, and the market share will decline, which will have a great adverse impact on the operating performance of the issuer. （2） Risk of R & D failure
In each period of the reporting period, the R & D expenses of the issuer were 25.9013 million yuan, 33.8223 million yuan, 32.6081 million yuan and 1996.55 million yuan respectively, accounting for 4.04%, 4.84%, 3.58% and 3.35% of the operating revenue respectively. In order to ensure the ability of continuous innovation, the issuer will maintain high investment in R & D expenses. If the R & D project fails, or relevant technologies fail to form products or realize industrialization, it will have an adverse impact on the issuer’s operating performance. （3） Risks of macroeconomic and downstream market fluctuations
The downstream market of the company is mainly distributed in industries such as electronics, automobile, home appliances and health appliances, which is closely related to the overall operation of macro-economy. In recent years, due to global inflation, negative growth in international trade, low international direct investment activities, rising debt levels in various countries, trade friction between China and the United States, and the epidemic situation of New Coronavirus pneumonia, macroeconomic fluctuations have fluctuated, and global economic growth has slowed down. If the global macro economy continues to be depressed or worsened in the future, it will have an adverse impact on the market demand of the company’s downstream industries, and then affect the company’s operating performance. （4） Risk of gross margin fluctuation
During the reporting period, the issuer’s comprehensive gross profit margin was 37.63%, 37.17%, 35.94% and 33.65% respectively, with a slight decline. Due to the fluctuation of macro-economy and downstream market, the rise of labor cost, the fluctuation of raw material price and the increasingly fierce market competition, the issuer’s operating income and operating cost fluctuate to a certain extent, and the issuer faces the risk of fluctuation of comprehensive gross profit margin. （5） Risk of improper control by actual controller
The actual controllers of the company are Zhuang Huiyang and Wang Yan, who jointly held 72.7105% of the equity of the company before the issuance. Although the company has established a corporate governance structure and internal control system that meet the requirements of Listed Companies in accordance with the requirements of China Securities Regulatory Commission and stock exchange, and the operation is effective, if the actual controller uses its control position to adversely affect or even improperly control the company’s business decisions, financial norms, personnel appointment and dismissal, etc, The interests of the company and other shareholders may be damaged. （6） Risk of issuance failure
The issuer plans to issue 31.2 million shares to the public. The investors’ subscription of the company’s shares in this public offering is mainly based on the judgment of the company’s current market value, future development prospect and other factors. Due to different investment preferences and different understanding of the industry and the company’s business, if the company’s value and future development prospect cannot be recognized by the investors, there may be insufficient subscription in this offering, This issue failed. 2、 Important commitments made by relevant entities of this issuance
Important commitments made by the issuer and its controlling shareholders, actual controllers, shareholders holding more than 5%, directors, supervisors and senior managers of the issuer, sponsors and securities service institutions of this issuance See “II. Important commitments made by relevant subjects of this offering” in “section XIII annex” of this prospectus for the specific contents of binding measures for failing to fulfill commitments and other matters. 3、 Arrangement of accumulated profits before this offering
As approved by the first extraordinary general meeting of the company in 2020, the accumulated undistributed profits (accumulated losses) before the issuance of the company shall be jointly enjoyed or borne by the new and old shareholders after the issuance according to the shareholding ratio after the issuance. 4、 Main financial information and operation after the audit deadline of financial report (I) main financial information and operation from January to September 2021
The audit deadline of the company’s financial report is June 30, 2021. UOB has reviewed the company’s consolidated and parent company’s balance sheet on September 30, 2021, consolidated and parent company’s income statement, consolidated and parent company’s cash flow statement, consolidated and parent company’s statement of changes in shareholders’ equity and notes to financial statements from January to September 2021, And issued dahuhezi [2021] 0011915 review report.
As of September 30, 2021, the total assets of the company were 1429.4075 million yuan, an increase of 188.1513 million yuan over the end of 2020. Among them, the current assets increased by 52.2517 million yuan compared with the end of 2020, mainly due to the increase of monetary capital, accounts receivable and inventory; Non current assets increased by 135.8996 million yuan compared with the end of 2020, mainly due to the increase in the amount of construction in progress of raised investment projects. The total liabilities of the company are 322576400 yuan, an increase of 27.8418 million yuan compared with the end of 2020, mainly due to the increase of current liabilities compared with the end of 2020.
From January to September 2021, the company’s operating performance maintained a rapid growth compared with the same period of the previous year, with an operating revenue of 91.166 million yuan, an increase of 55.99% over the same period of the previous year. After deducting non recurring profits and losses, the net profit attributable to the shareholders of the parent company was 147.4072 million yuan, an increase of 61.22% over the same period of the previous year. The main reasons are: 1. Affected by the epidemic from January to September 2020, the total revenue of the company is relatively small; 2. As the product quality, delivery date and service of injection molded parts are gradually recognized by customers, the company maintains a long-term and stable cooperative relationship with injection molded parts customers, the downstream market demand increases, the company obtains more orders and the income of injection molded parts increases more; 3. The health products launched under the background of strong public health awareness have been continuously recognized by the market, and with the rigid demand abroad and the gradual release of China’s market potential, the relevant income of the company’s health products has increased significantly.
From the audit deadline of the company’s financial report to the signing date of this prospectus, the company’s business condition is normal and its business performance is good. The company’s business model, composition of major customers and suppliers, tax policies and other major matters that may affect the judgment of investors have not changed significantly, and the operation is in good condition.
The company has disclosed the main financial information and operating conditions after the audit deadline of the financial report in “XVI. Main financial information and operating conditions after the audit deadline of the financial report” of “Section VIII Financial Accounting Information and management analysis” of this prospectus. （2） Expected operation from January to December 2021
Combined with the orders on hand and expected orders, the issuer predicts that the operating revenue from January to December 2021 will be 1089896600 yuan to 1244896600 yuan, with a change range of 19.70% to 36.72% over the same period of the previous year, and the net profit attributable to the shareholders of the parent company will be 191193300 yuan to 218130800 yuan, with a change range of 18.93% to 35.69% over the same period of the previous year, The net profit attributable to the shareholders of the parent company after deducting non recurring profits and losses was 177667800 yuan to 204.6054 million yuan, with a change range of 30.60% to 50.40% over the same period of the previous year. The above performance forecast from January to December 2021 does not constitute the company’s profit forecast or profit commitment.
catalogue
Declare that 2 overview of this offering 3. Tips on major events four
1、 Special risk tips four
2、 Important commitments made by relevant entities of this issuance five
3、 Arrangements for accumulated profits before this offering five
4、 Main financial information and operation after the audit deadline of the financial report 5 catalog Section 1 interpretation 12 section II Overview eighteen
1、 Basic information of the issuer and the intermediary of this offering eighteen
2、 Overview of this offering eighteen
3、 Main financial data and financial indicators of the issuer twenty
4、 Main business of the issuer V. issuer’s innovation, creation and creative features, scientific and technological innovation, model innovation, business type innovation and new and old
Industrial Integration twenty-one
6、 Specific listing criteria selected by the issuer twenty-five
7、 Important matters such as special arrangements for corporate governance of the issuer twenty-six
8、 Purpose of raised funds Section 3 overview of this offering twenty-seven
1、 Basic information of this offering twenty-seven
2、 The parties involved in this offering twenty-seven
3、 The relationship between the issuer and the intermediaries related to this offering twenty-nine
4、 Important dates related to this offering 29 Section IV risk factors twenty-nine
1、 Innovation risks thirty
2、 Technical risks thirty
3、 Operational risk thirty
4、 The risk of improper control by the actual controller thirty-three
5、 Financial risk thirty-three
6、 Risks of investment projects with raised funds thirty-five
7、 Other risks Section V basic information of the issuer thirty-eight
1、 Basic information of the issuer thirty-eight
2、 The establishment of the issuer and the changes in share capital and shareholders during the reporting period thirty-eight
3、 Major asset restructuring of the issuer during the reporting period fifty-three
4、 Equity structure of the issuer fifty-three
5、 Information of the issuer’s subsidiaries and participating companies fifty-five
6、 Basic information of major shareholders and actual controllers seventy-two
7、 Share capital of the issuer eighty-one
8、 Directors, supervisors, senior managers and other core members of the issuer
